Samantha Bove, Francesca Arezzo, Gennaro Cormio, Erica Silvestris, Alessia Cafforio, Maria Colomba Comes, Annarita Fanizzi, Giuseppe Accogli, Gerardo Cazzato, Giorgio De Nunzio, Brigida Maiorano, Emanuele Naglieri, Andrea Lupo, Elsa Vitale, Vera Loizzi, Raffaella Massafra
{"title":"Explainable machine learning for predicting recurrence-free survival in endometrial carcinosarcoma patients.","authors":"Samantha Bove, Francesca Arezzo, Gennaro Cormio, Erica Silvestris, Alessia Cafforio, Maria Colomba Comes, Annarita Fanizzi, Giuseppe Accogli, Gerardo Cazzato, Giorgio De Nunzio, Brigida Maiorano, Emanuele Naglieri, Andrea Lupo, Elsa Vitale, Vera Loizzi, Raffaella Massafra","doi":"10.3389/frai.2024.1388188","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial cancer, accounting for about 5% of all uterine cancers and 15% of deaths from uterine cancers. The treatment can be complex, and the prognosis is poor. Its increasing incidence underscores the urgent requirement for personalized approaches in managing such challenging diseases.</p><p><strong>Method: </strong>In this work, we designed an explainable machine learning approach to predict recurrence-free survival in patients affected by endometrial carcinosarcoma. For this purpose, we exploited the predictive power of clinical and histopathological data, as well as chemotherapy and surgical information collected for a cohort of 80 patients monitored over time. Among these patients, 32.5% have experienced the appearance of a recurrence.</p><p><strong>Results: </strong>The designed model was able to well describe the observed sequence of events, providing a reliable ranking of the survival times based on the individual risk scores, and achieving a C-index equals to 70.00% (95% CI, 59.38-84.74).</p><p><strong>Conclusion: </strong>Accordingly, machine learning methods could support clinicians in discriminating between endometrial carcinosarcoma patients at low-risk or high-risk of recurrence, in a non-invasive and inexpensive way. To the best of our knowledge, this is the first study proposing a preliminary approach addressing this task.</p>","PeriodicalId":33315,"journal":{"name":"Frontiers in Artificial Intelligence","volume":"7 ","pages":"1388188"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659245/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Artificial Intelligence","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frai.2024.1388188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial cancer, accounting for about 5% of all uterine cancers and 15% of deaths from uterine cancers. The treatment can be complex, and the prognosis is poor. Its increasing incidence underscores the urgent requirement for personalized approaches in managing such challenging diseases.
Method: In this work, we designed an explainable machine learning approach to predict recurrence-free survival in patients affected by endometrial carcinosarcoma. For this purpose, we exploited the predictive power of clinical and histopathological data, as well as chemotherapy and surgical information collected for a cohort of 80 patients monitored over time. Among these patients, 32.5% have experienced the appearance of a recurrence.
Results: The designed model was able to well describe the observed sequence of events, providing a reliable ranking of the survival times based on the individual risk scores, and achieving a C-index equals to 70.00% (95% CI, 59.38-84.74).
Conclusion: Accordingly, machine learning methods could support clinicians in discriminating between endometrial carcinosarcoma patients at low-risk or high-risk of recurrence, in a non-invasive and inexpensive way. To the best of our knowledge, this is the first study proposing a preliminary approach addressing this task.